Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer

Jonathan P. Evans; Boleslaw K. Winiarski; Paul A. Sutton; Robert P. Jones; Lorenzo Ressel; Carrie A. Duckworth; D. Mark Pritchard; Zhi-Xiu Lin; Vicky L. Fretwell; Elizabeth M. Tweedle; Eithne Costello; Christopher E. Goldring; Ian M. Copple; B. Kevin Park; Daniel H. Palmer; Neil R. Kitteringham

doi:10.18632/oncotarget.26625

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer

PDF | How to cite

Oncotarget. 2019; 10:685-685. https://doi.org/10.18632/oncotarget.26625

Metrics: PDF 1774 views | ?

Jonathan P. Evans^1,*, Boleslaw K. Winiarski^2,*, Paul A. Sutton¹, Robert P. Jones¹, Lorenzo Ressel³, Carrie A. Duckworth⁴, D. Mark Pritchard⁴, Zhi-Xiu Lin⁵, Vicky L. Fretwell¹, Elizabeth M. Tweedle¹, Eithne Costello¹, Christopher E. Goldring², Ian M. Copple², B. Kevin Park², Daniel H. Palmer^1,6 and Neil R. Kitteringham²

¹ Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
² MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
³ Department of Veterinary Pathology, Institute of Veterinary Science, University of Liverpool, Liverpool, United Kingdom
⁴ Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
⁵ School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China
⁶ Clatterbridge Cancer Centre, Liverpool, United Kingdom
^* Joint first authorship

Published: January 18, 2019

This article has been corrected: The correct Author name is given below:

Vicky L. Fretwell

Original article: Oncotarget. 2018; 9:27104-27116. DOI: https://doi.org/10.18632/oncotarget.25497.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26625

Publication Alerts

Corrections:

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer